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The factors regulat ing the magnitude of histamine-
mediated reactions in the skin need to be e lucidated if 
we are to devise a rational therapy for urticaria. At-
tempts to prevent biosynthesis of histamine in vivo have 
proved unrewarding. Depletion of histamine stores in 
skin by repeated provocation of release until a state of 
tolerance has been reached has proved a useful proce-
dure in patients with cold urticaria, but because of its 
inconvenience it requires a high degree of motivation. 
Attempts to moderate histamine secretion by mast cells, 
for example, by drugs that increase cyclic AMP, includ-
ing isoproterenol and theophylline, have not met with 
success. Doxantrazole, a systemically adminis tered com-
pound with actions resembling the better known diso-
dium cronioglycate, has been effective in suppressing 
histamine release evoked by cold in patients with cold 
urticaria, but there has been a puzzling discrepancy 
between clinical response and reduction in histamine 
release. Rate of enzymic histamine degradation may be 
an important factor in determining the magnitude of 
histamine-mediated reactions in skin, Degradation of 
histamine in human skin takes place by N-methylation, 
catalyzed by N-methyl transferase. Blockade of hista-
mine degradation in the guinea pig leads to amplification 
of the his tamine-mediated passive cutaneous anaphy-
laxis reaction in this species. Histamine-mediated skin 
reactions can be modulated by blockade of vascular 
histamine receptors. Recently the presence of 2 sub-
classes of histamine receptors, HI and H 2, on human skin 
blood vessels, has been established. Combined treatment 
by classical H I antihistamines and H2 antihistamines 
offers a possibility of more effective antihistamine treat-
ment. 
Mast cells secrete their preformed histamine content in re-
sponse to an appropriate physiologic or pathologic stimulus. 
Whether or not the mast cell in man secretes active substances 
besides histamine is an open question . Certainly release of other 
mediators, including slowly reacting substance of anaphylaxis 
[1] and eosinophil chemotactic factor of anaphylaxis [2], can be 
demonstrated in tissues in which histamine release from mast 
cells has been evoked, but t he celis from which they originate 
have yet to be identified. 
Evidence t hat histamine, derived from mast celis, is involved 
in the production of urticarial wealing reactions comes from 
various sources. Histamine can be recovered from urticated 
skin in cutaneous mastocytosis by dermal perfusion of the 
urticated skin [3], and the findin gs are similar in the dermo-
graphic skin of factitious urticaria [3], and in antigen-stimulated 
immediate hypersensitivity reactions in skin [4]. 
Studies on venous blood drained from cold-urticated skin in 
cold urticaria patients have also yielded elevated histamine 
levels [5]. T he technique is elementary. The arm is immersed 
in water chilled to a predetermined temperature, and venous 
blood samples are withdrawn from an indwelling cannula in the 
ipsilateral antecubital vein . Histamine is recognized by its abil-
ity to produce a contraction of the isolated guinea pig ileum 
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preparation that can be abolished by the histamine HI antag-
onist mepyramine (pyrilamine). The changes in histamine con-
centrations in venous blood, drained from forearm skin, before 
and after one or more cold challenges are shown in Fig l. 
In a series of patients with cold urticaria that we have studied 
in this way we have usually found an association between cold-
evoked histamine release and urtication. 
Therefore, it is important to consider the factors that regulate 
the magnitude of histamine-mediated reactions in skin because 
this information may reveal new approaches to therapeutic 
control of histamine-mediated skin responses. These factors 
include the capacity of mast cells to synthesize histamine, the 
size of histamine stores, the intracellular enzym atic mechanisms 
leading to histamine secretion, the rate of decay of extracellular 
histamine activity after secretion, and the sensitivity of blood 
vessels to histamine. 
Synthesis of histamine from its precursor histidine takes 
place in mast cells and is catalyzed by the enzyme histidine 
decarboxylase. Although many compounds have been shown to 
inhibit histamine biosynthesis in vitro, most lack selectivity and 
none have proved to be effective inhibitors of histamine syn-
thesis in vivo. 
Systematic depletion of stored histamine by repeated evoca-
tion of the release mechanism is an effective treatment in most 
patients with cold urticaria [5]. We immersed the skin of 5 
patients for 5 min in water at 15°C at hourly intervals until no 
visible urtication occurred. The interval was then extended to 
2 hr, and if no further urtication occurred, to 4, 6, 8, 12, and 
eventually 24 hr or more. In one patient it was impossible to go 
beyond 4 hr; the remainder were controlled by 24 hourly 
immersions. 
The possibility that release or secretion of preformed hista-
mine from th e mast cell can be prevented deserves attention. 
We have carried out detailed studies on the biochemical regu-
lation of antigen-stimulated histamine secretion from human 
skin mast cells. To do this, we used sliced human mastectomy 
skin that has been passively sensitized by human reaginic 
serum. These slices behaved on antigen challenge as in vitro 
models of passive cutaneous anaphylactic reactions of the 
Prausnitz-Kustner type [6]. Although there were some impor-
tant differences, there also were many similarities between 
release of histamine from mast cells and release of histamine 
from human basophils. For example, release is calcium-depend-
ent, and it is inhibited by drugs that increase cellular levels of 
cyclic AMP [7,8]. Attempts to suppress both urticaria and 
experimentally evoked histamine release reactions in skin with 
systemic drugs like isoprenaline and theophylline alone and in 
combinat ion in order to increase cellular cyclic AMP levels 
have, in our hands, been unsuccessful. 
Release is energy-dependent, and in human skin it sh ows 
only moderate sensitivity to low temperatures [6]. Even at 
temperatures as low as 20°C, there is little inhibition of release. 
Perhaps this finding might be related to the fact that in man 
skin is normally cooler than deeper tissues. 
Another way of reducing release of histamine is suggested by 
the advent of the cromone drugs currently used for the treat-
ment of asthma [9]. Cromolyn (disodium cromoglycate) pre-
vents secretion or release of histamine from mast cells, but its 
precise mode of action is as yet ill understood. Cromoglycate 
itself is poorly soluble and so is administered by inhalation. 
However, the recent availabil ity of doxantrazole, a compound 
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FIe 1. The upper and lower tracings show contractile respon es of 2 
isolated guinea pig ileum preparations (the n.umbers refer to histamine 
concentrations in ng in standard reference solu tions). A represents the 
histamine concentration before cold challenge and B the response from 
blood drained from cold-urticated skin. C, the response to a second cold 
challenge 20 min after A , was associated wi th reduced urtication. D is 
the response after cold challenge of a clinically cold-tolerant arm after 
induction of tolerance by repeated immersion in cold water. That these 
responses were all due to histamine is demonstrated by the fact that 
the second ileum preparation mounted in series with the first failed to 
respond to either authentic standard histamine solutions or any of the 
test samples after treatment with mepyramine (pyrilamine) (10-' M ). 
with actions resembling cromoglycate that can be given system-
ically [10], gave us an opportunity to evalua te the effect of this 
drug on cold-evoked histamine r elease and urt ication in patien ts 
with cold urticaria [11]. The following findings in one pa tient 
with cold urt icaria, who was typical of the remainder , illustrate 
the action of systemic doxa ntrazole. 
Cold-evoked histamine release was m easured in the cold-
challenged arm as previously described, and the r esulting ery-
t hema was assessed visually . Before doxantrazole treatment, 
the venous blood histamine levels reached 35 ng/mi 2 min after 
cold immersion; 2.5 hI' after a single systemic dose of doxantra -
zole the corresponding value in the con tralateral arm in re-
sponse to cold challenge was 15 ng/ml. After 2.5 weeks of 
doxantrazole treatmen t, there was little or no histamine r elease 
on cold challenge. In this patient there was an excellent corre-
la tion between the diminished histamine releases a nd clinical 
improvement on doxantrazole, but t his could not be said of all 
patients since, a lthough all showed diminished histamine 
release, some showed comparatively little clinical benefi t. 
The degree of vasodilat ion and wealing in response to hista-
mine release from m ast cells is dependent on the local concen-
tration of r eleased histamine, and this is partly dependent on 
the ra te of decay of histamine activity. The factors influencing 
the ra t e of decay include diffusion, lympha tic clearance, and 
local enzym atic degradation. It is a surprising fact that lit tle or 
no attention has been given to the r egulating influence of 
enzymatic histamine degradat ion on the m agni tude of hista-
mine responses in skin , despite the fact that t he skin is a major 
target organ for histamine-media ted responses. 
Two major pathways are recognized for enzymatic histamine 
degradation. The first depends on oxida tive deamination to 
imidazole acetic acid, a nd is catalyzed by diamine oxidase. The 
second, ca talyzed by N-methyl transferase, involves N-meth-
ylation to methyl histamine, which in turn is conver ted to 
methyl imidazole acetic acid. This reaction requires the methyl-
donor cofactor S-adenosyl methionine. In the skin of t he guinea 
pig oxidative deamination predominates [12]. T he products of 
incubation of homogenized huma n skin with histamine have 
been studied by a radiochemical method combined wit h thin-
layer chromatography [13]. 
Human breast skin homogenate was incubated with C I4 _la_ 
beled histamine in the presence and a bsence of the methyl 
donor S -adenosyl m ethionine, and the products were sepamted 
by thin-layer chromatography. In the absence of the cofactor, 
t he radioactive material eluted fro m the chromatoplate after 
incubation consisted mainly of unaltered histamine. H owever, 
if S-adenosyl methionine was present, there was a reduct ion in 
the a mount of unalter ed histamine recovered, and the appear-
ance of radioactivity cochromatographing with methyl hista-
mine. There was no radioactivity in the zone corresponding 
with imidazole acetic acid . It is clear, therefore, that under our 
experimental condit ions the major pathway for catabolism of 
histamine in human skin is N -methylation . 
The importance of the enzym atic degradation of histamine 
in r egulating the severi ty of wt icarial and other allergic reac-
tions involving histamin e and mast cells can be gauged from 
consideration of th e passive cutaneous a naphylaxis (P CA) re-
action in the guinea pig [12], which can be used as an animal 
m odel of urt icaria. Several dilutions of ovalbumin antiserum 
were injected intradermally; 72 hr later the a nimals were chal-
lenged int ravenously wi th ovalbumin a ntigen and a dye. The 
animals were divided into 2 groups. One was pretreated with 
aminoguanidine, a specific inhibitor of diamine oxidase, in 
concentrations adequate to block diamine oxidase, the predOm-
inant histamine-degrading enzyme in guinea pig skin. T he 
control group was given saline only. T he P CA titer was higher 
in the aminogu anidine-treated animals. The PCA t iter in the 
con trol group was 1:16, but in the aminogua nidine group it 
ranged from 1:32 to 1:64. More striking was the effect of ami-
noguanidine on t he magnitude of the P CA reaction . 
Fig 2 shows a typical result . The blockade of oxidative 
deamination r esulted in near doubling the size of the PCA 
reaction. The a mplifying effect of inhibition of enzymatic his-
tamine degradation on t he P CA reaction clearly suggests that, 
at least in the guinea pig, histamine-mediated reactions ar e 
regulated by enzym atic histamine degradation in skin [12]. 
The effectiveness of histamine released from mast cells on 
blood vessels depends to a large degree on the h istamine recep-
tors of those vessels. These a re only now beginning to be 
72 hr PCA Reaction 
Antiserum dilution as Indica ted 
4. 4 • 8. 8 • 
16 . 16 • 
Sa line Aminoguanidine 
FIe 2. Effect of aminoguanidine (6 mg in 1.0 ml of 0.154 M NaCI given 
intraperitoneally) on the guinea pig PCA reaction. Resul ts in a repre-
sentative animal from the control (saline-injected) group and fro m the 
test (aminoguanidine-treated) group are illustrated. Dilu ted pooled 
serum fro m ovalbumin-sensitized guinea pigs (0.1 ml in 0.154 M NaC!) 
was injected in tradermally into the shaved dorsal skin of normal male 
guinea pigs; 72 hI' later the animals were injected with 1 mg 5 x 
crystallized ovalbumin i.v. together, with 0.25% Evans blue (l.O ml per 
injection) in saline, and after a period of 45 min, the animals were killed 
and the reactions on the inner surface of the dorsal skin were read. 
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adequately characterized despite the fact that the response of 
human skin to histamine was described in detail by Lewis 
nearly 60 years ago. New information about the nature of 
histamine receptors should do much to rationalize an tihista-
mine therapy. 
T he existence of 2 classes of histamine receptors, H I and Hz, 
was first proposed by Ash and Schild in 1966 [14]. Subsequently 
the distribution of HI and H z receptors between differen t tissues 
was established, and the specific blockade of the Hz receptors 
by a pharmacological antagonist , burimamide, was reported 
[15]. T hese findings prompted explora tion of the possibility 
that the existence of H z as well as HI receptors might explain 
the observation familiar to clinicians that antihistamines are 
only partially effective in the suppression of urticari al weals 
and other histamine reactions in human skin. T hat human skin 
blood vessels possess Hz as well as H I receptors has been shown 
by studies on the responses of human skin to the histamine 
analogues 2-methyl histamine, an H I agonist, and 4-methyl 
histamine, an H 2 agonist [16]. Both agonists cause erythema, 
wealing, and a variable amount of itching and pain. The ery-
thema due to 2-methyl histamine is bright red and involves an 
axon reflex flare since it traverses a tigh t elastic band. In 
contrast, erythema due to the H 2 agonist 4-methyl histamine is 
dull red arid is limited by the band. Thus, the axon refl ex 
appears to be an H I action of histamine. 
T he actions of chlorpheniramine, an HI ant ihistamine, and 
cimetidine, a potent and selective H 2 antihistamine, on ery-
thema due to 2-methyl and 4-methyl histamine are of great 
interest. Dose-response curves were constructed for erythema 
before and after oral administration of chlorpheniramine 0 1' 
cimetidine [16]. Three doses of each agonist were given intra-
dermally in 17 subjects. Chlorpheniramine, as expected , caused 
reduction of erythema due to histamine, but cimetidine, which 
only blocks H 2 receptors, caused little or no inhibition. 
Results with 4-methyl histamine were also of special interest. 
Unexpectedly, chlorpeniramine as well as cimetidine inhibited 
erythema due to this Hz agonist. Although chlorpheniramine is 
a recognized H I antagonist, its action on H 2 receptors appar-
ently has not been studied. Thus, the inhibitory action of 
chlorpheniramine on erythema due to 4-methyl histamine could 
be the resul t of a lack of specificity of either the former or the 
latter. A third possibility is t hat 4-methyl histamine causes 
endogenous histamine release. Essentially similar results were 
obtained with wealing due to 2- and 4-methyl histamine. 
In summary, the abili t ies of 2- and 4-methyl histamine to 
evoke erythema and wealing in the skin, and the differential 
effects of cimetidine and chlorpheniramine on these reactions 
indicate the existence of H I and H 2 receptors on human skin 
blood vessels and offer a possible explanation of the failure of 
conventional HI antihistamines to reliably suppress urticarial 
wealing. 
Released histamine normally activates both HI and H 2 recep-
tors. Blockade of H I receptors by conventional antihistamines 
does not prevent stimulation of H 2 receptors, but a combination 
of H I and H 2 antagonists should bring abou t more complete 
suppression of histamine-mediated reactions than either drug 
alone. T o test this hypothesis, we studied the effects of chlor-
pheniramine and cimetidine, both alone and in combina tion , 
and of a placebo on erythema and wealing due to a range of 
concentrations of his tamine in 12 volunteer subjects by a dou-
ble-blind method [17]. Cimetidine alone caused a significant 
Vol. 71, No. 1 
diminu tion in erythema, and the combined treatment caused a 
significantly greater reduction than either drug alone. S imilar 
results were achieved with the histamine weal, although the 
greater suppression by the combined antagonists did not reach 
statistical significance. T he 48/80 erythema and wealing gave 
similar results. 
Clearly, the ability of the HI antagonist plus the H 2 antagonist 
to produce greater suppression of histamine reactions than 
either drug alone raises the possibili ty of a more refined ap-
proach to the pharmacologic regula tion of mast cell histamine 
reactions in human skin. 
A systematic study of the events linking stimulation of the 
skin with the responses of skin blood vessels to histamine 
released fro m mast cells can give insight into both intrinsic and 
extrinsic pharmacologic regulatory mechanisms on the mast 
cell. This approach is already yielding promising new leads to 
the therapeutic control of inflammatory skin diseases involving 
mast cells. 
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